Dear Shareholders,
Today, the Securities and Futures Commission ("SFC") announced its decision on Samsung Biologics' alleged accounting infringement issue. Samsung Biologics was accused of insufficient disclosure of notes regarding Biogen's call option in the company's audit reports from FY2012 to FY2015. The SFC called for assignment of independent auditors at the company for 3 years, the resignation of the company's utive in charge, and filing a complaint with the prosecutor’s office for further investigation.
Samsung Biologics' accounting treatments were conducted in accordance with the International Financial Reporting Standards ("IFRS") after careful consultation with its independent auditors. The SFC's announcement today is very unfortunate despite the company's efforts to prove its legality.
Samsung Biologics has strived to prove its legality to protect the interests of all stakeholders, clients and shareholders by providing full cooperation during all stages of the Financial Supervisory Service's audit and also the recent deliberations in the Accounting Oversight Deliberation Committee and the SFC.
The company will put forth its best efforts to prove that its accounting treatment had been legitimate ? even considering the possibility of filing an administrative lawsuit. Regardless, Samsung Biologics will stay focused on its business to strive to increase shareholders' value.
Sincerely,
Samsung Biologics
?
Dear Shareholders,
Today, the Securities and Futures Commission ("SFC") announced its decision on Samsung Biologics' alleged accounting infringement issue. Samsung Biologics was accused of insufficient disclosure of notes regarding Biogen's call option in the company's audit reports from FY2012 to FY2015. The SFC called for assignment of independent auditors at the company for 3 years, the resignation of the company's utive in charge, and filing a complaint with the prosecutor’s office for further investigation.
Samsung Biologics' accounting treatments were conducted in accordance with the International Financial Reporting Standards ("IFRS") after careful consultation with its independent auditors. The SFC's announcement today is very unfortunate despite the company's efforts to prove its legality.
Samsung Biologics has strived to prove its legality to protect the interests of all stakeholders, clients and shareholders by providing full cooperation during all stages of the Financial Supervisory Service's audit and also the recent deliberations in the Accounting Oversight Deliberation Committee and the SFC.
The company will put forth its best efforts to prove that its accounting treatment had been legitimate – even considering the possibility of filing an administrative lawsuit. Regardless, Samsung Biologics will stay focused on its business to strive to increase shareholders' value.
Sincerely,
Samsung Biologics
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO